| Name |
|---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of differentiated medicines that address health problems and meaningfully improve patients' lives....
Benzinga Rankings give you vital metrics on any stock – anytime.
You can purchase shares of Kymera Therapeutics (NASDAQ:KYMR) through any online brokerage.
Other companies in Kymera Therapeutics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Kymera Therapeutics has a consensus price target of $114.97.
The stock price for Kymera Therapeutics (NASDAQ: KYMR) is $110.85 last updated October 22, 2026 at 4:01 PM EDT.
There are no upcoming dividends for Kymera Therapeutics.
Kymera Therapeutics does not have any upcoming earnings scheduled.
There is no upcoming split for Kymera Therapeutics.
Kymera Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
